Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Yu
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Keros Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research seeks to determine in animal models the dose and duration of treatment with AZD0530 for suppressing bone formation following surgical removal of bone in patients with fibrodysplasia ossificans progressiva. The company is focused on inhibition of ALK2, the genetic driver for fibrodysplasia ossificans progressive (FOP). The company has previously licensed IP related to HO from Partners, would likely be interested in licensing the new IP if the project is successful.
Repositioning AZD0530 for surgical treatment of fibrodysplasia ossificans progressiva
Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that results in the replacement of soft tissues with bone, causing profound immobility, impaired quality of life, and reduced life expectancy. Attempts to remove abnormal bone in FOP to improve mobility are almost always met with the return of bone formation, and often worsening of immobility. Based on promising animal model results, this proposal tests whether an existing experimental drug, AZD0530, that has already been tested for safety in hundreds of human patients, could be effective and safe in suppressing bone formation following surgical removal of bone in patients with FOP, thereby providing a strategy for restoring quality of life and function for a condition that currently has no effective therapies.
Filed on October 12, 2018.
Tell us what you know about Paul Yu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Paul Yu filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $20,000 - $39,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $20,000 - $39,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | $10,000 - $19,999 |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | Value cannot be readily determined |
| Paul Yu | Brigham and Women's Hospital | Conflict of Interest | Keros Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.